Your Insulin Therapy

August 2004
American Family Physician;8/1/2004, Vol. 70 Issue 3, p511
Academic Journal
Presents information on insulin therapy. Kinds of insulin; Symptoms of low blood sugar; Mealtime insulin type and dose.


Related Articles

  • Cdk5-dependent regulation of glucose-stimulated insulin secretion. Fan-Yan Wei; Nagashima, Kazuaki; Ohshima, Toshio; Saheki, Yasunori; Yun-Fei Lu; Matsushita, Masayuki; Yamada, Yuichiro; Mikoshiba, Katsuhiko; Seino, Yutaka; Matsui, Hideki; Tomizawa, Kazuhito // Nature Medicine;Oct2005, Vol. 11 Issue 10, p1104 

    Tight glycemic control in individuals with diabetes mellitus is essential to prevent or delay its complications. Present treatments to reduce hyperglycemia mainly target the ATP-sensitive K+ (KATP) channel of pancreatic beta cells to increase insulin secretion. These current approaches are often...

  • 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and 1,2,3,4,7,8-Hexachlorodibenzo-p-Dioxin (HxCDD) Alter Body Weight by Decreasing Insulin-Like Growth Factor I (IGF-I) Signaling. Croutch, Claire R.; Lebofsky, Margitta; Schramm, Karl-Werner; Terranova, Paul F.; Rozman, Karl K. // Toxicological Sciences;May2005, Vol. 85 Issue 1, p560 

    2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) affects glycemia due to reduced gluconeogenesis; when combined with a reduction in feed intake, this culminates in decreased body weight. We investigated the effects of steady-state levels of TCDD (loading dose rates of 0.0125, 0.05, 0.2, 0.8, and 3.2...

  • Improved Insulin Sensitivity by GLUT12 Overexpression in Mice. Purcell, Scott H.; Aerni-Flessner, Lauren B.; Willcockson, Alexandra R.; Diggs-Andrews, Kelly A.; Fisher, Simon J.; Moley, Kelle H. // Diabetes;May2011, Vol. 60 Issue 5, p1478 

    OBJECTIVE--Evidence suggests that insulin-sensitive glucose transporters (GLUTs) other than GLUT4 may exist. To investigate whether GLUT12 may represent another insulin-sensitive GLUT, transgenic (TG) mice that overexpress GLUT12 were characterized. RESEARCH DESIGN AND METHODS--TG mice that...

  • Low-dose guar improves diabetic control. Jones, D. B.; Lousley, S.; Jelfs, R.; Slaughter, P.; Carter, R. D.; Mann, J. I. // Journal of the Royal Society of Medicine;Jul1985, Vol. 78 Issue 7, p546 

    Twenty diabetic outpatients (12 non-insulin-treated and 8 insulin-treated) were given guar granulate in a dose of 10 g daily for two months in order to study the effect on glycaemic control and lipid levels. Mean glycosylated haemoglobin levels (HbA1c%) fell from 1.1± 2.0% pre-guar to 10.5...

  • 5-Aminoimidazole-4-Carboxamide-1-β-D-Ribofuranoside Causes Acute Hepatic Insulin Resistance In Vivo. Pencek, R. Richard; Shearer, Jane; Camacho, Raul C.; James, Freyja D.; Lacy, D. Brooks; Fueger, Patrick T.; Donahue, E. Patrick; Snead, Wanda; Wasserman, David H. // Diabetes;Feb2005, Vol. 54 Issue 2, p355 

    The infusion of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) causes a rise in tissue concentrations of the AMP analog 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranotide (ZMP), which mimics an elevation of cellular AMP levels. The purpose of this work was to determine the...

  • Glucose monitoring.  // RN;Nov2004, Vol. 67 Issue 11, p4 

    Presents a guide for glucose monitoring. Newer types of blood glucose meter; Adjustments that can be made on insulin dosage; Ways of monitoring carbohydrate intake.

  • Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Heise, Tim; Nosek, Leszek; Rønn, Birgitte Biilmann; Endahl, Lars; Heinemann, Lutz; Kapitza, Christoph; Draeger, Eberhard; Rønn, Birgitte Biilmann // Diabetes;Jun2004, Vol. 53 Issue 6, p1614 

    The aim of this randomized double-blind study was to compare the within-subject variability of the glucose-lowering effect of a novel insulin analog, insulin detemir, with that of insulin glargine and NPH insulin in people with type 1 diabetes. Fifty-four subjects (32 males and 22 females, age...

  • Prediabetes therapy and beta-cell function. Kuritzky, Louis // Clinical Cardiology Alert;May2010 Primary Care, p9 

    The article discusses a Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial, which examined the effect of rosiglitazone and ramipril on beta-cell function in prediabetes (pDM) subjects with impaired glucose tolerance (IGT) or impaired fasting glucose (IFT).

  • Assessment of Beta-Cell Responsiveness by IVGTT in Patients with Type 2 Diabetes: an Exploratory Trial in Patients Who Have Substituted Exenatide for Insulin. Davis, Stephen; Johns, Don; Northrup, Justin; Maggs, David; Bhole, Deepak; Xu, Hangtao; Brodows, Robert // Diabetes;Jun2007 Supplement 1, Vol. 56, pA138 

    In this 16-week pilot study, we explored the safety of substituting exenatide (5 µg BID for 4 wks, 10 µg BID thereafter) for insulin in patients who were using insulin in combination with oral agents. Patients with type 2 diabetes were randomized to either substitute exenatide for insulin...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics